Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Shivani Kumaresan

Hims & Hers Health Stock Gains On Solid Q1, FY22 Outlook

  • Hims & Hers Health Inc (NYSE:HIMS) reported fourth-quarter FY21 sales growth of 104% year-on-year, to $84.7 million, beating the consensus of $76.79 million.
  • The average order value for the quarter was $74. Q4 2021 ending member subscriptions grew 95% year-over-year to 609,000.
  • The gross profit margin contracted 400 basis points Y/Y to 73%, and the gross profit rose 94.7% Y/Y to $62.1 million.
  • The loss from operations widened to $(21.6) million.
  • The company held $247 million in cash and equivalents as of December 31, 2021.
  • EPS of $(0.15) missed the analyst consensus of $(0.07).
  • The adjusted EBITDA loss widened to $(7.1) million.
  • Outlook: Hims & Hers sees Q1 sales of $90 million - $93 million versus the consensus of $77.92 million.
  • The company expects FY22 sales of $365 million - $380 million against the consensus of $350.75 million.
  • Price Action: HIMS shares are trading higher by 14.5% at $4.78 in premarket on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.